Literature DB >> 23934027

Immune regulation by CD52-expressing CD4 T cells.

Ban-Hock Toh1, Tin Kyaw, Peter Tipping, Alex Bobik.   

Abstract

T-cell regulation by CD52-expressing CD4 T cells appears to operate by two different and possibly synergistic mechanisms. The first is by its release from the cell surface of CD4 T cells that express high levels of CD52 that then binds to the inhibitory sialic acid-binding immunoglobulin-like lectins-10 (Siglec-10) receptor to attenuate effector T-cell activation by impairing phosphorylation of T-cell receptor associated lck and zap-70. The second mechanism appears to be by crosslinkage of the CD52 molecules by an as yet unidentified endogenous ligand that is mimicked by a bivalent anti-CD52 antibody that results in their expansion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934027      PMCID: PMC4003202          DOI: 10.1038/cmi.2013.35

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  31 in total

1.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

2.  CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

Authors:  Tomoko Watanabe; Jun-ichi Masuyama; Yoshiaki Sohma; Hiroko Inazawa; Kaori Horie; Kumiko Kojima; Yasunori Uemura; Yumi Aoki; Shuji Kaga; Seiji Minota; Toshiyuki Tanaka; Yasunori Yamaguchi; Tetsuto Kobayashi; Isao Serizawa
Journal:  Clin Immunol       Date:  2006-06-22       Impact factor: 3.969

Review 3.  Siglecs--the major subfamily of I-type lectins.

Authors:  Ajit Varki; Takashi Angata
Journal:  Glycobiology       Date:  2005-07-13       Impact factor: 4.313

4.  Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein.

Authors:  G Hale
Journal:  Immunotechnology       Date:  1995-12

5.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

6.  Cd52, known as a major maturation-associated sperm membrane antigen secreted from the epididymis, is not required for fertilization in the mouse.

Authors:  Ryo Yamaguchi; Kazuo Yamagata; Hidetoshi Hasuwa; Emiko Inano; Masahito Ikawa; Masaru Okabe
Journal:  Genes Cells       Date:  2008-08       Impact factor: 1.891

7.  Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.

Authors:  Heinz Wiendl; Bernd Kieseier
Journal:  Nat Rev Neurol       Date:  2013-01-29       Impact factor: 42.937

8.  Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate.

Authors:  Elina Kivi; Kati Elima; Kristiina Aalto; Yvonne Nymalm; Kaisa Auvinen; Erkki Koivunen; Diana M Otto; Paul R Crocker; Tiina A Salminen; Marko Salmi; Sirpa Jalkanen
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

9.  Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.

Authors:  Tam Nguyen Dinh; Tin Soe Kyaw; Peter Kanellakis; Kelly To; Peter Tipping; Ban-Hock Toh; Alexander Bobik; Alex Agrotis
Journal:  Circulation       Date:  2012-07-31       Impact factor: 29.690

Review 10.  Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.

Authors:  Lisa Costelloe; Joanne Jones; Alastair Coles
Journal:  Expert Rev Neurother       Date:  2012-03       Impact factor: 4.618

View more
  9 in total

1.  Establishment a CHO Cell Line Expressing Human CD52 Molecule.

Authors:  Kadijeh Tati; Mahsa Yazdanpanah-Samani; Amin Ramezani; Elham Mahmoudi Maymand; Abbas Ghaderi
Journal:  Rep Biochem Mol Biol       Date:  2016-10

Review 2.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

Review 3.  Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.

Authors:  María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2021-04-23

4.  Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura.

Authors:  Contessa E Edgar; Deirdra R Terrell; Sara K Vesely; Jonathan D Wren; Igor M Dozmorov; Timothy B Niewold; Michael Brown; Fang Zhou; Mark Barton Frank; Joan T Merrill; Johanna A Kremer Hovinga; Bernhard Lämmle; Judith A James; James N George; A Darise Farris
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

5.  Multiregion single-cell sequencing reveals the transcriptional landscape of the immune microenvironment of colorectal cancer.

Authors:  Wei Wang; Yu Zhong; Zhenkun Zhuang; Jiarui Xie; Yueer Lu; Chengzhi Huang; Yan Sun; Liang Wu; Jianhua Yin; Hang Yu; Zhiqiang Jiang; Shanshan Wang; Chunqing Wang; Yuanhang Zhang; Yilin Huang; Chongyin Han; Zhenggang Zhong; Jialin Hu; Ying Ouyang; Huisheng Liu; Mengya Yu; Xiaochan Wei; Dandan Chen; Lizhen Huang; Yong Hou; Zhanglin Lin; Shiping Liu; Fei Ling; Xueqing Yao
Journal:  Clin Transl Med       Date:  2021-01

6.  High expression of CD52 in adipocytes: a potential therapeutic target for obesity with type 2 diabetes.

Authors:  Rui Mao; Fan Yang; Yu Zhang; Hongtao Liu; Pengsen Guo; Yanjun Liu; Tongtong Zhang
Journal:  Aging (Albany NY)       Date:  2021-03-11       Impact factor: 5.682

7.  A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma.

Authors:  Qianli Ma; Yang Chen; Fei Xiao; Yang Hao; Zhiyi Song; Jin Zhang; Katsuhiro Okuda; Sang-Won Um; Mario Silva; Yoshihisa Shimada; Chaozeng Si; Chaoyang Liang
Journal:  Transl Lung Cancer Res       Date:  2021-03

8.  Long-Term Elevated Siglec-10 in Cerebral Spinal Fluid Heralds Better Prognosis for Patients with Aneurysmal Subarachnoid Hemorrhage.

Authors:  Sen Gao; Xun-Zhi Liu; Ling-Yun Wu; Zheng Peng; Xiang-Xin Chen; Han Wang; Yue Lu; Zong Zhuang; Qian Tan; Chun-Hua Hang; Wei Li
Journal:  Dis Markers       Date:  2022-09-21       Impact factor: 3.464

Review 9.  Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.

Authors:  Kaja Kasarello; Dagmara Mirowska-Guzel
Journal:  Immunotargets Ther       Date:  2021-07-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.